Regional Director of the Mountain States Hemophilia NetworkHemophilia Center, Oregon Health & Science University, Portland, OR, USAPortland, Oregon, United States
OC 52.5 - Phase 3 HOPE-B trial of etranacogene dezaparvovec in severe/moderately severe hemophilia B: A post hoc responder analysis of participants who received full dose and responded to treatment
Tuesday, June 27, 202311:45 – 12:00 ET
